A5052930494- Bacteriophages and microbial interactions
- Microbial infections and disease research
- Antibiotic Resistance in Bacteria
- Genomics and Phylogenetic Studies
- Respiratory viral infections research
- Respiratory Support and Mechanisms
- Plant Virus Research Studies
- Evolution and Genetic Dynamics
- Mechanical Circulatory Support Devices
- Cardiac Arrest and Resuscitation
- Probiotics and Fermented Foods
- Cancer Research and Treatments
- Pneumonia and Respiratory Infections
- Airway Management and Intubation Techniques
- SARS-CoV-2 detection and testing
- Vibrio bacteria research studies
- Nosocomial Infections in ICU
- Intensive Care Unit Cognitive Disorders
Inserm
2021-2025
Hôpital Louis-Mourier
2019-2025
Université Paris Cité
2019-2025
Institut Pasteur
2021-2025
Centre National de la Recherche Scientifique
2022-2025
Infection, Anti-microbiens, Modélisation, Evolution
2020-2024
Assistance Publique – Hôpitaux de Paris
2020-2024
Sorbonne Paris Cité
2023
Délégation Paris 7
2021
The clinical (re)development of bacteriophage (phage) therapy to treat antibiotic-resistant infections faces the challenge understanding dynamics phage-bacteria interactions in vivo context. Here, we develop a general strategy coupling vitro and experiments with mathematical model characterize interplay between phage bacteria during pneumonia induced by pathogenic strain Escherichia coli. allows estimation several key parameters for therapeutic efficacy. In particular, it quantifies impact...
Abstract Predicting how phages can selectively infect specific bacterial strains holds promise for developing novel approaches to combat infections and better understanding microbial ecology. Experimental studies on phage-bacteria interactions have been mostly focusing a few model organisms understand the molecular mechanisms which makes particular strain susceptible given phage. However, both bacteria are extremely diverse in natural contexts. How well concepts learned from well-established...
Phage therapy of ventilator-associated pneumonia (VAP) is great interest due to the rising incidence multidrug-resistant bacterial pathogens. However, natural or therapy-induced immunity against therapeutic phages remains a potential concern. In this study, we investigated innate and adaptive immune responses two different phage cocktails targeting either Pseudomonas aeruginosa Escherichia coli—two VAP-associated pathogens—in naïve mice without confounding effects infection. Active...
ABSTRACT Bacteria exposed to bactericidal treatment, such as antibiotics or bacteriophages (phages), often develop resistance. While phage therapy is proposed a solution the antibiotic resistance crisis, bacterial emerging during remains poorly characterized. In this study, we examined large population of phage-resistant extra-intestinal pathogenic Escherichia coli 536 clones that emerged from both in vitro (non-limited liquid medium) and vivo (murine pneumonia) conditions. Genome sequencing...
In the treatment of bacterial infections, use antibiotics or bacteriophages (phages) is limited by ability bacteria to develop resistance. The resistance frequency depends on exposure antibacterials.
Nosocomial infections contribute to 10-20% of ICU mortality, depending on the ventilation status, making ventilator-associated pneumonia (VAP) most common fatal hospital-acquired infection. Common bacterial lung pathogens include multidrug-resistant (MDR) bacteria, like carbapenem-resistant P. aeruginosa, K. pneumoniae, A. baumannii and E. coli, which are listed as "critical priority" bacteria by WHO. Bacteriophage (phage) therapy could possibly be an attractive option for VAP therapy. In a...
Abstract Combined use of virulent bacteriophages (phages) and antibiotics reduces the severity difficult-to-treat Pseudomonas aeruginosa infections in many patients. In vitro methods that attempt to reproduce more than one physiological state pathogens can provide a valuable assessment antibacterials like phages. Here, by measuring bacterial killing kinetics individual replication different growth conditions, including biofilms human lung epithelial cell line, we elucidated factors...
<title>Abstract</title> Bacterial multidrug resistance poses an urgent challenge for the treatment of critically ill patients developing ventilator-associated pneumonia (VAP). Phage therapy, a potential alternative when conventional antibiotics fail, has been unsuccessful in first clinical trials used alone. Whether combining with phages may enhance effectiveness remains to be tested experimental models. Here, we murine model <italic>Pseudomonas aeruginosa</italic>-induced VAP compare...
A bstract Bacteria exposed to killing agents such as antibiotics or viruses develop resistance. While phage therapy, the use of bacteriophages (phages) for treating bacterial infections, is proposed answer antibiotic resistance crisis, phages remains poorly characterized during treatment. We studied a large population phage-resistant extra-intestinal pathogenic Escherichia coli 536 clones emerging from both in vitro (non-limited liquid medium) and vivo (murine pneumonia) conditions. Genome...
Abstract Objectives Bacteria developing resistance compromise the efficacy of antibiotics or bacteriophages (phages). We tested association these two antibacterials to circumvent resistance. Methods With Hollow Fiber Infection Model (HFIM), we mimicked concentration profile ciprofloxacin in lungs patients treated orally for Pseudomonas aeruginosa infections and independently, a single inhaled administration phages (one phages). Results Each treatment selects antibiotic-or phage-resistant...
Summary The clinical (re)development of phage therapy to treat antibiotic resistant infections requires grasping specific biological properties bacteriophages (phages) as antibacterial. However, identification optimal dosing regimens is hampered by the poor understanding phage-bacteria interactions in vivo. Here we developed a general strategy coupling vitro and vivo experiments with mathematical model characterize interplay between bacterial dynamics during pneumonia induced pathogenic...